BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhu K, Kakkar R, Chahal D, Yoshida EM, Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol 2023; 29(37): 5327-5338 [PMID: 37899788 DOI: 10.3748/wjg.v29.i37.5327]
URL: https://www.wjgnet.com/1007-9327/full/v29/i37/5327.htm
Number Citing Articles
1
Sirada Limwongse, Paninnuch Chatpattanasiri, Phonnaphat Phuphuang, Krisada Tungthaweethong, Keerati Sutheerayongprasert, Watkornphat Aunprom-Me, Chayanis Kositamongkol, Pochamana Phisalprapa. Cost-utility analysis of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease in Thailand. World Journal of Hepatology 2026; 18(10): 123353 doi: 10.4254/wjh.123353
2
Rong Ren, Yanxia Pei, Lufei Kong, Yixin Shi. The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease. Journal of Diabetes and its Complications 2025; 39(2) doi: 10.1016/j.jdiacomp.2024.108932
3
Mohit Kehar, Samar H. Ibrahim, Charina M. Ramirez, Saista Asif Amin, Tamir Diamond, Saeed Mohammad. Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction‐associated steatotic liver disease. Journal of Pediatric Gastroenterology and Nutrition 2024; 79(3) doi: 10.1002/jpn3.12236
4
Omnia A. Hawary, Walaa Wadie, Yasmin A. M. El-Said, Omnia F. Hassan. Repurposing of semaglutide by targeting SIRT1 and TGF‐β/Smad signaling in hepatic fibrosis. Naunyn-Schmiedeberg's Archives of Pharmacology 2026; 399(3) doi: 10.1007/s00210-025-04675-x
5
Matthew Peverelle, Jonathan Ng, James Peverelle, Ryan D. Hirsch, Adam Testro. Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis. World Journal of Gastroenterology 2023; 29(47): 6165-6167 doi: 10.3748/wjg.v29.i47.6165
6
Fabiana Dolovitsch de Oliveira, Samira Mohamad Khalil, Emmily Daiane Buarque de Santana Sato, Matheus Henrique Gonçalves de Souza, Gilmara Coelho Meine. Efficacy and Safety of Fibroblast Growth Factor 21 Analogues for Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis. Annals of Nutrition and Metabolism 2024;  doi: 10.1159/000541583
7
François Briand, Caroline Dubroca, Guillaume Wettstein, Estelle Grasset, Natalia Breyner, Claire Bigot, Rana Assaly, Pierre Broqua, Thierry Sulpice. Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD. European Journal of Pharmacology 2025; 1003 doi: 10.1016/j.ejphar.2025.177945
8
Hui Wu, Zi-Heng Zhang, Ting Ye, Jia-Ni Chen, Tao-Hsin Tung, Jian-Sheng Zhu. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1783429
9
Hong-Tai Tzeng, Wei-Chia Lee. Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity. Nutrients 2024; 16(9) doi: 10.3390/nu16091388
10
Amedeo Lonardo, Ralf Weiskirchen. Liver and obesity: a narrative review. Exploration of Medicine 2025; 6 doi: 10.37349/emed.2025.1001334
11
Shu Niu, Shu-Chun Chen, Chen-Xi Wang, Lin Yue, Shu-Qi Wang. Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice. World Journal of Hepatology 2025; 17(10): 110402 doi: 10.4254/wjh.v17.i10.110402
12
D. M. Antsiferova, O. M. Koteshkova, M. B. Antsiferov. Have we done everything possible for a patient with type 2 diabetes mellitus combined with obesity?. Meditsinskiy sovet = Medical Council 2025; (16) doi: 10.21518/ms2025-446
13
Moaz Safwan, Mariam Safwan Bourgleh, Shahad Abdullah Alotaibi, Eman Alotaibi, Abdulsalam Al-Ruqi, Fathiya El Raeya. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis. Annals of Saudi Medicine 2025; 45(2) doi: 10.5144/0256-4947.2025.129
14
Xiao‐yan You, Xiang‐yang Li, Hui Wang, Guo‐ping Zhao. Development of NAFLD‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation. Cell Proliferation 2026; 59(4) doi: 10.1111/cpr.70118
15
Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic. MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development. Current Issues in Molecular Biology 2024; 46(7) doi: 10.3390/cimb46070376
16
V. T. Ivashkin, O. M. Drapkina, M. V. Maevskaya, K. L. Raikhelson, S. V. Okovityi, M. S. Zharkova, V. R. Grechishnikova, D. I. Abdulganieva, S. A. Alekseenko, M. D. Ardatskaya, I. G. Bakulin, N. V. Bakulina, P. O. Bogomolov, V. V. Breder, E. V. Vinnitskaya, N. I. Geyvandova, E. V. Golovanova, V. B. Grinevich, V. L. Doshchitsin, E. N. Dudinskaya, E. V. Ershova, K. B. Kodzoeva, I. V. Kozlova, K. A. Komshilova, Yu. V. Konev, N. V. Korochanskaya, Yu. V. Kotovskaya, Yu. A. Kravchuk, I. D. Loranskaya, I. V. Maev, A. I. Martynov, S. N. Mekhtiev, E. E. Mishina, M. Yu. Nadinskaia, I. G. Nikitin, M. F. Osipenko, O. D. Ostroumova, Ch. S. Pavlov, N. V. Pogosova, V. G. Radchenko, G. E. Roytberg, R. G. Saifutdinov, A. A. Samsonov, P. V. Seliverstov, S. I. Sitkin, L. V. Tarasova, A. I. Tarzimanova, O. N. Tkacheva, E. I. Tkachenko, E. A. Troshina, S. V. Turkina, Yu. P. Uspenskiy, Yu. A. Fominykh, O. V. Khlynova, Yu. V. Tsyganova, M. Sh. Shamkhalova, O. O. Sharkhun, M. V. Shestakova. Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2025; 35(1) doi: 10.22416/1382-4376-2025-35-1-94-152
17
Tilemachos Koutouratsas, Markos Kalligeros, Mark Michael, Siddharth Das, Sophia C Mylonakis, Eleftherios Mylonakis. GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort study. Age and Ageing 2026; 55(9) doi: 10.1093/ageing/afag281
18
Husam Albarmawi, Firas Dabbous, Abdalla Aly, Alia Yousif, Samuel Huse, Maximilian Jara, Andres Quintero, Eric Lawitz. Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide. Current Medical Research and Opinion 2025; 41(11) doi: 10.1080/03007995.2025.2596430
19
Yasser Fouad, Wafaa A Abdelghany, Reem El Sheemy. Anti-obesity medications, the new frontiers in metabolic dysfunction-associated fatty liver disease: Efficacy, limitations, and future directions. World Journal of Hepatology 2026; 18(5): 118303 doi: 10.4254/wjh.v18.i5.118303
20
Jahnavi Udaikumar, Rithish Nimmagadda, Vindhya Vasini Lella, Kesava Manikanta Achuta, Satwik Kuppili, Suraj Reddy Avula, Raiya Sarwar. The Comparative Safety and Efficacy of Resmetirom and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review. Pharmacoepidemiology 2025; 4(3) doi: 10.3390/pharma4030014
21
Ermina Stratina, Carol Stanciu, Robert Nastasa, Sebastian Zenovia, Remus Stafie, Adrian Rotaru, Tudor Cuciureanu, Cristina Muzica, Catalin Sfarti, Irina Girleanu, Horia Minea, Oana Petrea, Laura Huiban, Stefan Chiriac, Ana-Maria Singeap, Oana Vlad, Camelia Cojocariu, Anca Trifan. New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease. Diagnostics 2024; 14(14) doi: 10.3390/diagnostics14141475
22
Devaraj Ezhilarasan. Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?. Journal of Gastroenterology and Hepatology 2025; 40(9) doi: 10.1111/jgh.17037
23
E. E. Mulyukova, E. L. Novikova, I. A. Skirdov, K. S. Usmanova, N. V. Yusifzade. Pharmacotherapy of metabolically associated fatty liver disease. Experimental and Clinical Gastroenterology 2026; (8) doi: 10.31146/1682-8658-ecg-240-8-156-163
24
Sultan Alfawaz, Abdulhadi Burzangi , Ahmed Esmat. Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review. Cureus 2024;  doi: 10.7759/cureus.67080
25
Fatima Ali Raza, Rafiya Altaf, Talha Bashir, Fatima Asghar, Rabiya Altaf, Sohaib Tousif, Aman Goyal, Aisha Mohammed, Mahnoor Faisal Mohammad, Mahfuza Anan, Sajjad Ali. Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review. Medicine 2024; 103(44) doi: 10.1097/MD.0000000000040364
26
Tereza Dusilová, Jan Kovář, Ivana Laňková, Lenka Thieme, Monika Hubáčková, Petr Šedivý, Dita Pajuelo, Martin Burian, Monika Dezortová, Denisa Miklánková, Hana Malínská, Petra Svobodová Šťastná, Rudolf Poledne, Milan Hájek, Martin Haluzík. Semaglutide Treatment Effects on Liver Fat Content in Obese Subjects with Metabolic-Associated Steatotic Liver Disease (MASLD). Journal of Clinical Medicine 2024; 13(20) doi: 10.3390/jcm13206100
27
Kathryn J Potter, Jackie Phinney, Tasha Kulai, Vicki Munro. Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of the Canadian Association of Gastroenterology 2025; 8(2) doi: 10.1093/jcag/gwae057
28
Megan O. Bensignor, Silva Arslanian, Mary Ellen Vajravelu. Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice. Current Opinion in Pediatrics 2024; 36(4) doi: 10.1097/MOP.0000000000001365
29
Antonio Saviano, Natascha Roehlen, Thomas F. Baumert. Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma. Seminars in Liver Disease 2024; 44(02) doi: 10.1055/s-0044-1785646
30
Giovanna McGinty, Robert Przemioslo. Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications. World Journal of Gastroenterology 2024; 30(27): 3264-3267 doi: 10.3748/wjg.v30.i27.3264
31
Maria Zasadzińska, Grzegorz Borowski, Piotr Bakuła, Kamila Jałocha. The Evolving Role of GLP-1 Receptor Agonists in MASLD: Current Evidence and Future Directions. Journal of Diabetology 2025; 16(3) doi: 10.4103/jod.jod_18_25
32
E.E. Mulyukova, E.L. Novikova, I.A. Skirdov, K.S. Usmanova, N.V. Yusifzade. Pharmacotherapy of the metabolically associated fatty liver disease. Russian Journal of Preventive Medicine 2025; 28(10) doi: 10.17116/profmed202528101103
33
Ildar Uzyanbaev, Sofya Timoshenko, Liudmila Spirina, Maria Matveeva. Novel Approaches to Diagnosing and Treating Non-alcoholic Fatty Liver Disease: Opportunities and Accomplishments. Current Drug Targets 2026; 27(13) doi: 10.2174/0113894501398066251211070417
34
Tzu‐Rong Peng, Hung‐Hong Lin, Tzu‐Ling Tseng, Ta‐Wei Wu, You‐Chen Chao. Clinical evidence of semaglutide for metabolic dysfunction‐associated steatotic liver disease (MASLD): An updated meta‐analysis. British Journal of Clinical Pharmacology 2026; 92(8) doi: 10.1002/bcp.70629
35
Naveed Sattar, Lyn D Ferguson, Matthew M Y Lee. From adiposity to multisystem morbidity: the case for weight loss as disease modification. The Lancet Diabetes & Endocrinology 2026; 14(11) doi: 10.1016/S2213-8587(26)00186-5
36
Iris van de Loo, Birgit Harbeck. Facharztwissen Endokrinologie und Diabetologie. 2026;  doi: 10.1007/978-3-662-71684-7_12
37
L. B. Lazebnik, S. V. Turkina, E. V. Golovanova. Targeted use of hepatoprotectors for the treatment of various stages of non-alcoholic fatty liver disease (fatty degeneration of the liver according to ICD 10) and associated comorbid conditions; tables for medical use. Experimental and Clinical Gastroenterology 2024; (10) doi: 10.31146/1682-8658-ecg-230-10-11-35
38
Klaudia Nowak, Krzysztof Łupina, Anna Romac, Aleksandra Kalisz, Łucja Ilkiewicz, Jakub Janczura. Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease. Annals of Pharmacotherapy 2025; 59(10) doi: 10.1177/10600280251322002
39
Sofia Rozani, Maria Dalamaga, Georg Weber, Robert Grützmann. Liver transplantation in the era of obesity: A metabolic public health crisis meets a surgical frontier. Metabolism Open 2025; 28 doi: 10.1016/j.metop.2025.100410
40
Connor Endsley, Shariq Ali, Karim Salhadar, Adam Woodward, Shea Garland, Julien Santelli, Mehdi Zeighami Salimabad, Liqiang Ren, Takeshi Yokoo, Ivan M. Rosado‐Mendez, David T. Fetzer, Caroline de Gracia Lux. Lipid Microparticle‐Based Phantoms Modeling Hepatic Steatosis for the Validation of Quantitative Imaging Techniques. Small Methods 2025; 9(8) doi: 10.1002/smtd.202500043
41
Mohamed Mahmoud Marey, Mohamed Belal, Abdelaziz A. Awad, Eslam Mohammed Rabea, Malak A. Hassan, Ahmed W. Abbas, Abdulqadir J. Nashwan. Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2024; 48(6) doi: 10.1016/j.clinre.2024.102357
42
Roberta Chianetta, Lydia Giannitrapani, Alessio Giuseppe Lipari, Assunta Brunone, Claudia Cannizzo, Roberto Citarrella, Maurizio Soresi, Antonio Liguori, Nadia Panera, Filomena Morisco, Luca Miele, Anna Licata. Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease. Biomolecules 2026; 16(6) doi: 10.3390/biom16060797
43
Aristomenis G. Alevizopoulos, Vasileios Vasilakos, Iakovos Kritikos, Maria Alevizopoulou, Eleni Korompoki, Theodora Psaltopoulou, Stavroula A. Paschou. Repurposing incretin-based therapies for alcohol use disorder: a systematic review of efficacy and safety relative to standard pharmacotherapies in a recent comparative context. Therapeutic Advances in Psychopharmacology 2026; 16 doi: 10.1177/20451253261457548
44
Emir Muzurović, Martin Haluzik, Ludek Horváth, Bogdan Vlacho, Didac Mauricio. Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease. Current Pharmaceutical Design 2026; 32(20) doi: 10.2174/0113816128378484250619080753
45
Pattern of Glycemic Status of Chronic Liver Disease Patients. TAJ: Journal of Teachers Association 2025; 38(4) doi: 10.70818/taj.v38i04.0434
46
Yue-Hua Yin, Li-Xuan Sang, Bing Chang. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1. World Journal of Gastroenterology 2023; 29(48): 6235-6238 doi: 10.3748/wjg.v29.i48.6235
47
Suleman Khan, Asad Jamal, Maria Qadri, Ibrahim Aslam Zai, Asim Shah, Adil Ahmed, Aizaz Anwar Khalid, Abbas Khan, F.N.U. Misbahuddin, Hammad Iftikhar, F.N.U. Sawaira, Muneeb Shad Mohmand, Ibrahim Khalil, Mobeen Khan, Somaiya Ahmed. Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment. Medicine 2026; 105(30) doi: 10.1097/MD.0000000000049916
48
Samira Mohamad Khalil, Matheus Henrique Gonçalves de Souza, Fabiana Dolovitsch de Oliveira, Emmily Daiane Buarque de Santana Sato, Gilmara Coelho Meine. Efficacy and safety of aldafermin for the treatment of metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2025; 49(5) doi: 10.1016/j.clinre.2025.102579